Aquestive Therapeutics (AQST) Operating Leases (2020 - 2026)

Aquestive Therapeutics' Operating Leases history runs 7 years deep, the most recent figure standing at $4.8 million for Q1 2026.

• On a quarterly basis, Operating Leases changed 0.02% year-over-year to $4.8 million in Q1 2026; TTM through Mar 2026 was $4.8 million, a 0.02% change from a year earlier, with the FY2025 full-year figure at $4.3 million, down 12.7% from the prior year.
• Operating Leases advanced to $4.8 million in Q1 2026 per AQST's latest filing, from $4.3 million in the prior quarter.
• Across five years, Operating Leases topped out at $6.0 million in Q2 2023 and bottomed at $1.5 million in Q2 2022.
• The 5-year median for Operating Leases is $5.1 million (2024), against an average of $4.7 million.
• Across the five-year window, Operating Leases tumbled 37.81% in 2022 and jumped 296.6% in 2023, its largest moves.
• Year by year, Operating Leases stood at $5.1 million in 2022, then rose by 6.18% to $5.4 million in 2023, then slipped by 7.98% to $5.0 million in 2024, then decreased by 12.7% to $4.3 million in 2025, then grew by 11.16% to $4.8 million in 2026.
• Per Business Quant, the three latest AQST Operating Leases figures stand at $4.8 million (Q1 2026), $4.3 million (Q4 2025), and $5.1 million (Q3 2025).